Suppr
超能文献

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

作者信息

Callery Mark P, Chang Kenneth J, Fishman Elliot K, Talamonti Mark S, William Traverso L, Linehan David C

机构信息

Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.

出版信息

Ann Surg Oncol. 2009 Jul;16(7):1727-33. doi: 10.1245/s10434-009-0408-6. Epub 2009 Apr 24.

DOI:10.1245/s10434-009-0408-6

PMID:19396496

Abstract

摘要

相似文献

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Ann Surg Oncol. 2009 Jul;16(7):1727-33. doi: 10.1245/s10434-009-0408-6. Epub 2009 Apr 24.

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Callery et al.

Ann Surg Oncol. 2009 Jul;16(7):1734-5. doi: 10.1245/s10434-009-0411-y. Epub 2009 Apr 24.

Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al.

Ann Surg Oncol. 2009 Jul;16(7):1745-50. doi: 10.1245/s10434-009-0410-z. Epub 2009 Apr 24.

Defining venous involvement in borderline resectable pancreatic cancer.

Ann Surg Oncol. 2010 Nov;17(11):2832-8. doi: 10.1245/s10434-010-1284-9. Epub 2010 Aug 20.

Pancreatic cancer.

Curr Probl Surg. 1999 Feb;36(2):59-152.

[Current aspects of diagnosis and therapy of pancreatic carcinoma].

Z Gastroenterol. 2002 Dec;40 Suppl 2:62-3. doi: 10.1055/s-2002-35889.

Imaging of pancreatic adenocarcinoma: update on staging/resectability.

Radiol Clin North Am. 2012 May;50(3):407-28. doi: 10.1016/j.rcl.2012.03.008. Epub 2012 Apr 6.

Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.

Ann Surg Oncol. 2009 Jul;16(7):1736-44. doi: 10.1245/s10434-009-0416-6. Epub 2009 Apr 23.

Radiology of pancreatic adenocarcinoma: current status of imaging.

J Gastroenterol Hepatol. 2008 Jan;23(1):23-33. doi: 10.1111/j.1440-1746.2007.05117.x.

Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.

Hematol Oncol Clin North Am. 2015 Aug;29(4):727-40. doi: 10.1016/j.hoc.2015.04.004. Epub 2015 Jun 9.

引用本文的文献

Advances in the Management of Pancreatic Cancer: Current Strategies and Emerging Therapies.

Int J Mol Sci. 2025 Jul 22;26(15):7055. doi: 10.3390/ijms26157055.

Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights.

World J Clin Oncol. 2025 Jul 24;16(7):106107. doi: 10.5306/wjco.v16.i7.106107.

Evaluation of Recurrence Risk in Irreversible Electroporation-Treated Pancreatic Adenocarcinoma Patients Using Radiomics Signatures.

Cancers (Basel). 2025 Jul 15;17(14):2338. doi: 10.3390/cancers17142338.

Efficacy of irreversible electroporation combined with immunotherapy versus irreversible electroporation alone in locally advanced pancreatic cancer: a propensity score-matched retrospective study.

Front Immunol. 2025 Jul 8;16:1620988. doi: 10.3389/fimmu.2025.1620988. eCollection 2025.

Surgery and neoadjuvant therapy in locally advanced pancreatic cancer: an umbrella review of survival, resection outcomes, and cost-effectiveness.

Gland Surg. 2025 Mar 31;14(3):529-542. doi: 10.21037/gs-24-421. Epub 2025 Mar 26.

Survival Outcomes in Nonmetastatic pT4 Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis Comparing Neoadjuvant Therapy and Upfront Surgery with Propensity Score Matching.

Asian Pac J Cancer Prev. 2025 Mar 1;26(3):847-859. doi: 10.31557/APJCP.2025.26.3.847.

Impact of Surgical Resection After Induction Gemcitabine Plus S-1-Based Chemoradiotherapy in Patients with Locally Advanced Pancreatic Ductal Adenocarcinoma: A Focus on UR-LA Cases.

Cancers (Basel). 2025 Mar 20;17(6):1048. doi: 10.3390/cancers17061048.

Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial.

J Immunother Cancer. 2025 Mar 26;13(3):e010222. doi: 10.1136/jitc-2024-010222.

Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis.

BJS Open. 2025 Mar 4;9(2). doi: 10.1093/bjsopen/zrae172.

A logistic regression model to predict long-term survival for borderline resectable pancreatic cancer patients with upfront surgery.

Cancer Imaging. 2025 Feb 5;25(1):10. doi: 10.1186/s40644-025-00830-y.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译